| Mercedes Noble, | |
|
777 Route 70 E Ste G101, Marlton, NJ 08053-2548 | |
| (856) 818-4020 | |
| (732) 479-6751 |
| Full Name | Mercedes Noble |
|---|---|
| Gender | Female |
| Speciality | Social Worker |
| Location | 777 Route 70 E Ste G101, Marlton, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609460732 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | (New Jersey) | Secondary |
| 104100000X | Social Worker | 44SL06784000 (New Jersey) | Primary |
| Entity Name | Middlesex Psychiatry & Tms Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053971572 PECOS PAC ID: 7315334000 Enrollment ID: O20220427002709 |
News Archive
Guerbet LLC, USA - Guerbet, a pioneer in the field of contrast agents with more than 80 years of experience, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for Lipiodol (Ethiodized Oil) Injection for management of patients with known hepatocellular carcinoma (HCC).
ON THIS "WORLDS AIDS DAY" we know many things will be discussed, but we're sure birth control will not be one of them. Project Prevention feels it is crucial to not just work towards curing infants with AIDS, but also to work on getting women living with HIV/AIDS on long term birth control to prevent future pregnancies that may result in suffering children.
Ichor Medical Systems (Ichor) and Profectus Biosciences (Profectus) announced today that they have entered into a long-term development, license, and supply Agreement providing Profectus with commercial access to Ichor's TriGrid™ Delivery System (TriGrid™) for the clinical development of its DNA vaccine programs, with an option for Ichor to co-develop.
There have been a reported over 115,000 cases and over 1,200 deaths due to measles in Madagascar according to reports. This is one of the largest epidemics of a vaccine preventable viral disease in the recent times, say experts.
Pharmaceutical firms "underinvest" in long-term research to develop new cancer-fighting drugs due to the greater time and cost required to conduct such research, according to a newly published study co-authored by MIT economists.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mercedes Noble, 60 W Landis Ave, Vineland, NJ 08360-8132 Ph: (856) 772-5809 | Mercedes Noble, 777 Route 70 E Ste G101, Marlton, NJ 08053-2548 Ph: (856) 818-4020 |
News Archive
Guerbet LLC, USA - Guerbet, a pioneer in the field of contrast agents with more than 80 years of experience, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for Lipiodol (Ethiodized Oil) Injection for management of patients with known hepatocellular carcinoma (HCC).
ON THIS "WORLDS AIDS DAY" we know many things will be discussed, but we're sure birth control will not be one of them. Project Prevention feels it is crucial to not just work towards curing infants with AIDS, but also to work on getting women living with HIV/AIDS on long term birth control to prevent future pregnancies that may result in suffering children.
Ichor Medical Systems (Ichor) and Profectus Biosciences (Profectus) announced today that they have entered into a long-term development, license, and supply Agreement providing Profectus with commercial access to Ichor's TriGrid™ Delivery System (TriGrid™) for the clinical development of its DNA vaccine programs, with an option for Ichor to co-develop.
There have been a reported over 115,000 cases and over 1,200 deaths due to measles in Madagascar according to reports. This is one of the largest epidemics of a vaccine preventable viral disease in the recent times, say experts.
Pharmaceutical firms "underinvest" in long-term research to develop new cancer-fighting drugs due to the greater time and cost required to conduct such research, according to a newly published study co-authored by MIT economists.
› Verified 3 days ago